Your browser doesn't support javascript.
loading
The Role of Losartan as a Potential Neuroregenerative Pharmacological Agent after Aneurysmal Subarachnoid Haemorrhage.
Wanderer, Stefan; Andereggen, Lukas; Mrosek, Jan; Kashefiolasl, Sepide; Marbacher, Serge; Konczalla, Jürgen.
Afiliação
  • Wanderer S; Department of Neurosurgery, Kantonsspital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.
  • Andereggen L; Cerebrovascular Research Group, Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland.
  • Mrosek J; Department of Neurosurgery, Goethe-University Hospital, Schleusenweg 2 - 16, 60528 Frankfurt am Main, Germany.
  • Kashefiolasl S; Department of Neurosurgery, Kantonsspital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.
  • Marbacher S; Cerebrovascular Research Group, Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland.
  • Konczalla J; Department of Neurosurgery, Goethe-University Hospital, Schleusenweg 2 - 16, 60528 Frankfurt am Main, Germany.
Int J Mol Sci ; 21(18)2020 Sep 05.
Article em En | MEDLINE | ID: mdl-32899487
BACKGROUND: Cerebral vasospasm (CVS) remains a major cause of delayed cerebral ischaemia following aneurysmal subarachnoid haemorrhage (SAH), making it a life-threatening type of stroke with high morbidity and mortality. Endothelin-1 is known as key player mediating a strong vasocontractile effect. Interestingly, losartan restores the impaired vasorelaxative ET(B1) receptor function in a non-competitive direct fashion. With this study, we aimed to investigate a potential losartan-dependent vasodilatory effect vice versa by inhibiting NO release through L-NAME, thus pushing forward concepts to alleviate vasospasm and possibly prevent ischaemia and neurodegeneration. METHODS: Cerebral vasospasm was induced by the use of an established double-injection rat model. Sprague-Dawley rats were culled on Day 3 after the ictus, and the vasospastic basilar artery was harvested for isometric investigations of the vessel tone. Ring segments were preincubated with and without L-NAME and/or losartan. RESULTS: Preincubation with L-NAME induced dose-dependent vasoconstriction via endothelin-1 in the non-SAH cohort, which was dose-dependently reduced by losartan. After SAH and dose-dependent endothelin-1 administration, maximal contraction was achieved in the control group without losartan. Furthermore, this maximal contraction was significantly decreased in the losartan group and was reversed by L-NAME. CONCLUSIONS: After SAH, losartan was shown to positively influence the ET(B1) receptor pathway in a non-competitive direct agonistic and indirect fashion. Losartan alleviated the maximum contraction triggered by endothelin-1. This effect was resolved due to NO inhibition by L-NAME. Considering this spasmolytic effect of losartan besides its already well-known effects (attenuating cerebral inflammation, restoring cerebral autoregulation and reducing epileptogenic activity) and alleviating early brain injury, losartan seems to have potential as a promising pharmacological agent after SAH.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Subaracnóidea / Losartan Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Subaracnóidea / Losartan Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article